Halozyme Therapeutics - HALO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $52.73
  • Forecasted Upside: 32.88%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
▼ -1.18 (-2.89%)

This chart shows the closing price for HALO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Halozyme Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HALO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HALO

Analyst Price Target is $52.73
▲ +32.88% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Halozyme Therapeutics in the last 3 months. The average price target is $52.73, with a high forecast of $66.00 and a low forecast of $42.00. The average price target represents a 32.88% upside from the last price of $39.68.

This chart shows the closing price for HALO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 11 contributing investment analysts is to moderate buy stock in Halozyme Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/20/2023BenchmarkReiterated RatingBuy ➝ Buy$50.00Low
10/19/2023HC WainwrightBoost TargetBuy ➝ Buy$60.00 ➝ $61.00Low
10/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$60.00Low
9/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$60.00Low
8/30/2023HC WainwrightReiterated RatingBuy ➝ Buy$60.00Low
8/15/2023HC WainwrightLower TargetBuy ➝ Buy$61.00 ➝ $60.00Low
8/10/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$60.00 ➝ $61.00Low
8/9/2023Piper SandlerBoost Target$46.00 ➝ $48.00Low
8/9/2023HC WainwrightLower Target$61.00 ➝ $60.00Low
7/24/2023HC WainwrightInitiated CoverageBuy$61.00Low
7/24/2023The Goldman Sachs GroupDowngradeBuy ➝ Neutral$43.00 ➝ $45.00Low
5/10/2023Piper SandlerUpgradeNeutral ➝ Overweight$46.00Low
3/27/2023Berenberg BankInitiated CoverageBuy$58.00Low
3/16/2023SVB LeerinkDowngradeOutperform ➝ Market Perform$42.00Low
3/16/2023SVB SecuritiesDowngradeOutperform ➝ Market Perform$42.00Low
3/16/2023Wells Fargo & CompanyLower TargetOverweight$65.00 ➝ $55.00Low
3/6/2023Morgan StanleyLower TargetOverweight$65.00 ➝ $64.00Low
2/23/2023JPMorgan Chase & Co.Lower TargetOverweight$54.00 ➝ $52.00Low
2/22/2023JMP SecuritiesReiterated RatingMarket Outperform$62.00 ➝ $66.00Low
1/11/2023SVB LeerinkLower TargetOutperform$62.00 ➝ $61.00Low
12/21/2022Morgan StanleyBoost TargetOverweight$53.00 ➝ $65.00Low
12/8/2022BenchmarkBoost TargetBuy$55.00 ➝ $68.00Low
11/28/2022Wells Fargo & CompanyInitiated CoverageOverweight$65.00Low
11/22/2022JPMorgan Chase & Co.Boost TargetOverweight$53.00 ➝ $54.00Low
11/14/2022SVB LeerinkBoost TargetOutperform$52.00 ➝ $62.00Low
11/9/2022JMP SecuritiesBoost TargetMarket Outperform$60.00 ➝ $62.00Low
9/9/2022Morgan StanleyInitiated CoverageOverweight$50.00Low
5/26/2022The Goldman Sachs GroupBoost TargetBuy$48.00 ➝ $60.00Low
5/23/2022SVB LeerinkInitiated CoverageOutperform$52.00Low
2/23/2022Piper SandlerLower Target$43.00 ➝ $42.00High
1/26/2022Piper SandlerLower Target$46.00 ➝ $43.00High
12/10/2021JMP SecuritiesReiterated RatingBuy$54.00High
11/24/2021Wells Fargo & CompanyLower TargetOverweight$60.00 ➝ $58.00Low
11/3/2021SVB LeerinkLower TargetOutperform$50.00 ➝ $48.00Low
11/3/2021JMP SecuritiesBoost TargetMarket Outperform$52.00 ➝ $55.00Low
6/14/2021Evercore ISIInitiated CoverageOutperformMedium
5/17/2021Piper SandlerReiterated RatingOverweight ➝ Neutral$50.00 ➝ $48.00N/A
5/17/2021SVB LeerinkInitiated CoverageOutperform$56.00Low
5/11/2021Piper SandlerDowngradeOverweight ➝ Neutral$50.00 ➝ $48.00High
1/25/2021BMO Capital MarketsBoost TargetOutperform$56.00 ➝ $65.00Low
1/21/2021BenchmarkBoost TargetBuy$46.00 ➝ $59.00Low
1/14/2021Piper SandlerBoost TargetOverweight$42.00 ➝ $50.00High
12/17/2020Berenberg BankInitiated CoverageBuy$50.00Medium
12/11/2020Smith Barney CitigroupBoost Target$29.00 ➝ $41.00Medium
11/24/2020BenchmarkBoost TargetBuy$39.00 ➝ $46.00Medium
11/23/2020Piper SandlerBoost Target$37.00 ➝ $42.00Low
11/16/2020Wells Fargo & CompanyBoost TargetOverweight$39.00 ➝ $60.00Low
11/2/2020Piper SandlerBoost TargetOverweight$31.00 ➝ $37.00High
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweightHigh
8/11/2020BMO Capital MarketsBoost TargetOutperform$35.00 ➝ $43.00High
8/11/2020Wells Fargo & CompanyBoost TargetOverweight$31.00 ➝ $39.00High
7/2/2020Piper SandlerBoost TargetOverweight$28.00 ➝ $31.00High
7/1/2020BenchmarkInitiated CoverageBuy$39.00Low
6/29/2020Piper SandlerReiterated RatingBuy$28.00High
6/15/2020CitigroupBoost TargetNeutral$18.00 ➝ $26.00Medium
5/12/2020BMO Capital MarketsBoost TargetOutperform$27.00 ➝ $35.00High
5/12/2020JPMorgan Chase & Co.Boost TargetOverweight$22.00 ➝ $23.00High
5/12/2020JMP SecuritiesBoost TargetPositive ➝ Outperform$24.00 ➝ $34.00High
5/4/2020Cantor FitzgeraldBoost TargetOverweight$35.00 ➝ $39.00Low
2/25/2020BarclaysBoost TargetEqual Weight$16.00 ➝ $20.00High
2/25/2020JPMorgan Chase & Co.Lower TargetOverweight$24.00 ➝ $22.00High
2/5/2020Piper SandlerUpgradeNeutral ➝ Overweight$18.00 ➝ $27.00Low
1/27/2020Cantor FitzgeraldReiterated RatingOverweight$27.00 ➝ $35.00Low
1/9/2020BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$17.00 ➝ $24.00High
1/8/2020The Goldman Sachs GroupInitiated CoverageBuy$24.00High
11/5/2019BarclaysUpgradeUnderweight ➝ Equal Weight$17.00 ➝ $16.00High
8/12/2019BarclaysReiterated RatingSell$17.00Medium
7/1/2019Cantor FitzgeraldBoost TargetOverweight$24.00 ➝ $27.00Low
5/8/2019Cantor FitzgeraldReiterated RatingBuyLow
2/28/2019Cantor FitzgeraldSet TargetBuy$24.00Medium
2/27/2019JMP SecuritiesReiterated RatingBuy$21.00Medium
2/4/2019Cantor FitzgeraldReiterated RatingBuy$24.00High
12/5/2018Cantor FitzgeraldReiterated RatingBuy$27.00Low
(Data available from 11/28/2018 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 15 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 15 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 11 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 13 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 17 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
  • 5 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 5 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Halozyme Therapeutics logo
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $39.68
Low: $38.99
High: $40.25

50 Day Range

MA: $37.40
Low: $33.32
High: $40.86

52 Week Range

Now: $39.68
Low: $29.85
High: $59.46


939,520 shs

Average Volume

1,189,151 shs

Market Capitalization

$5.24 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Halozyme Therapeutics?

The following equities research analysts have issued stock ratings on Halozyme Therapeutics in the last twelve months: Benchmark Co., Berenberg Bank, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, StockNews.com, SVB Leerink LLC, SVB Securities, The Goldman Sachs Group, Inc., TheStreet, and Wells Fargo & Company.
View the latest analyst ratings for HALO.

What is the current price target for Halozyme Therapeutics?

11 Wall Street analysts have set twelve-month price targets for Halozyme Therapeutics in the last year. Their average twelve-month price target is $52.73, suggesting a possible upside of 32.9%. JMP Securities has the highest price target set, predicting HALO will reach $66.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $42.00 for Halozyme Therapeutics in the next year.
View the latest price targets for HALO.

What is the current consensus analyst rating for Halozyme Therapeutics?

Halozyme Therapeutics currently has 3 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for HALO.

What other companies compete with Halozyme Therapeutics?

How do I contact Halozyme Therapeutics' investor relations team?

Halozyme Therapeutics' physical mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The biopharmaceutical company's listed phone number is 858-794-8889 and its investor relations email address is [email protected]. The official website for Halozyme Therapeutics is www.halozyme.com. Learn More about contacing Halozyme Therapeutics investor relations.